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The use of synthetic colloids (SCs), particularly hydroxyethyl starch (HES), in people has 
changed in recent years following new evidence raising concerns about their efficacy 
and safety. Although fluid therapy guidelines for small animals are often extrapolated 
from human medicine, little information exists on current practice in veterinary medi-
cine. The objective of the present study was to investigate current fluid selection, use 
of plasma volume expanders including SCs, and recent changes in their use in small 
animal practice. An Internet-based survey was conducted, inviting veterinarians to report 
their practices in fluid resuscitation and colloid osmotic pressure support, their choice of 
SC, and perceived adverse effects and contraindications associated with SC use. There 
were 1,134 respondents from 42 countries, including 46% general practitioners and 
38% diplomates. Isotonic crystalloids, HES, and hypertonic saline were chosen by most 
respondents for fluid resuscitation, and HES by 75% of respondents for colloid osmotic 
support. Dextran and gelatin were used by some European respondents. Human serum 
albumin was used more than canine albumin but 45% of respondents, particularly 
those from Australia and New Zealand, used no albumin product. The majority (70%) 
of respondents changed their practice regarding SCs in recent years (mostly by limiting 
their use), largely due to safety concerns. However, only 27% of respondents worked in 
an institution that had a general policy on SC use. Impaired renal function, coagulopathy, 
and hypertension were most often considered contraindications; impaired coagulation 
tests and increased respiratory rate were the most frequently perceived adverse effects. 
The use of HES remains widespread practice in small animals, regardless of geographic 
location. Nevertheless, awareness of safety issues and restrictions on the use of SCs 
imposed in human medicine seems to have prompted a decrease in use of SCs by vet-
erinarians. Given the paucity of evidence regarding efficacy and safety, and differences 
in cohorts between human and veterinary critical care patients, studies are needed to 
establish evidence-based guidelines specific for dogs and cats.
Keywords: dextran, fluid therapy, gelatin, hydroxyethyl starch, plasma expanders, synthetic colloids
Abbreviations: AKI, acute kidney injury; COP, colloid osmotic pressure; CRI, constant rate infusion; HES, hydroxyethyl starch; 
ICU, intensive care unit; RCT, randomized clinical trial; SC, synthetic colloid.
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inTrODUcTiOn
Crystalloids and colloids have been widely used for plasma 
volume expansion in human and veterinary medicine for many 
decades (1–3). However, there is no general consensus in human 
and veterinary medicine as to the selection of fluid for plasma 
volume expansion despite numerous reviews and guidelines 
(4–9). Indeed, previous national and international surveys and 
observational studies found that fluid therapy practices are 
determined more by empirical preference than scientific evi-
dence or physiological principles, with marked geographical and 
institutional disparity (1, 3, 10, 11). In recent years, randomized 
clinical trials (RCTs) and meta-analyses in human medicine 
have challenged previous concepts on the safety and efficacy of 
synthetic colloids (SCs), showing no benefit over crystalloids 
and, in some cases, linking the use of hydroxyethyl starch (HES) 
with acute kidney injury (AKI) and increased mortality (12–15). 
Although these findings have been disputed (16, 17), pharma-
covigilance authorities have listed HES as contraindicated in 
septic and other critically ill patients, restricting its use in many 
countries (18, 19).
Recommendations for fluid resuscitation in small animals 
are often based on extrapolation from human medicine and 
veterinary experts’ opinions (2, 7, 9). As human critical care 
practice faced evidence questioning the benefit and restricting 
the use of SCs, small animal medicine is put to the challenge 
of scrutinizing its own practices with regards to fluid therapy. 
Merely adopting guidelines set forth in human medicine may not 
be wholly appropriate in small animals, given substantial differ-
ences in human and veterinary perioperative and intensive care 
unit (ICU) cohorts and the availability of species-specific blood 
products. Moreover, the use of SCs in constant rate infusions 
(CRIs) for colloid osmotic pressure (COP) support seems to be 
a practice unique to veterinary medicine, lacking corresponding 
data or trials in human medicine.
This paper presents the results of an international Internet-
based survey evaluating current fluid therapy practices and 
factors influencing fluid selection in small animals. The survey 
was designed to question how fluids are used by veterinarians 
from different institutions and countries, the extent to which 
their practice may have changed over recent years, and examine 
the perceived risks and benefits associated with SC use.
MaTerials anD MeThODs
survey composition and characteristics
A commercial cloud-based survey development service 
(SurveyMonkey®, www.surveymonkey.com) was used to gene rate 
the questionnaire and gather participant responses. The question 
formats used were single- and multiple-answer multiple-choice, 
dichotomous questions, scaled and Likert-type ranking, and 
frequency scales with categorical or numerical ranking. All 
questions provided closed or combined closed/open answers 
whereby an “other” option provided a free-text field if none of 
the closed answers were valid. A total of 80 questions were devel-
oped, whereby contingency/filter questions were used to guide 
respondents to only those questions to which they were suited 
(Data Sheet S1 in Supplementary Material).
The survey was designed in two parts. An initial general part 
(Part 1) asked questions regarding respondent characteristics, 
qualifications, experience and area of practice, general use of 
fluids for resuscitation and COP support, and the preferred type 
of SC used. The second specific part (Part 2) asked questions 
about SC use, perceived adverse effects and contraindications, 
and participants’ recent changes in SC practices.
The study was approved by the Vetsuisse University IRB pro-
cedures. A preliminary survey was distributed to a pilot group 
(21 people) of in-house diplomates, residents, and interns. Questions 
were then amended for the final survey based on their feedback 
regarding question perspicuity and survey completion time.
Data collection and analysis
A cover letter with the main investigator’s contact information, 
explaining the purpose of the survey, assuring confidentiality 
and encouraging recipients to invite their colleagues to partici-
pate was then distributed with a link to the survey to veterinary 
organizations (Data Sheet S2 in Supplementary Material). This 
was achieved by contacting organizations and requesting them 
to distribute the link to their members and/or post it on their 
homepages, and directly by email to members of organizations via 
LISTSERVs. In addition, some institutional heads of veterinary 
faculties were directly contacted with the request to distribute the 
survey within their institution and to their referring veterinar-
ians (Data Sheet S3 in Supplementary Material). The survey was 
opened on 11th April 2016 and was closed on 14th May 2016.
All questions in Part 1 required an answer and only data from 
respondents answering all 17 questions were included for data 
analysis. For Part 2, the number of questions that required a 
response differed between respondents due to contingency ques-
tions. Responses to all questions in Part 2 were included.
resUlTs
results—Part 1
A total of 1,134 respondents completed at least Part 1 of the 
survey (Data Sheet S4 in Supplementary Material).
Respondent Characteristics
Respondents were 394 men and 740 women from 42 different 
countries. These included 658 (58%) from the USA and Canada, 
395 (35%) from Europe, 54 (5%) from Australia and New Zealand, 
and 27 (2%) from 17 other countries (Figure 1). The workplace 
setting of respondents was 489 (43%) in private practice, 319 
(28%) in a university hospital, and 326 (29%) in a specialty or 
other type of practice. These included primary care, referral, and 
mixed primary and referral practices (Figure 2). The number of 
years’ experience of the respondents was ≤5 years in 237 (21%), 
6–10 years in 322 (28%), 11–15 years in 233 (21%), 16–20 years in 
126 (11%), and >20 years in 216 (19%) of respondents.
Respondents included 525 (46%) general practitioners, 435 
(38%) board-certified diplomates, 95 (8%) residents, 28 (3%) 
interns, and 51 (5%) others/unspecified. Diplomates included 
FigUre 2 | Frequency chart showing the qualifications and case types seen 
by the 1,134 survey respondents.
FigUre 1 | Frequency chart showing the geographic distribution of the 
1,134 survey respondents. Countries represented by 30 or more 
respondents are shown separately within each geographic area.
FigUre 3 | Frequency chart showing the relative frequency with which the 
1,134 survey respondents use intravenous solutions for fluid resuscitation. 
CRYS, crystalloids; HTS, hypertonic saline; HES, hydroxyethyl starch; DEX, 
dextran; GEL, gelatin; ALB, albumin.
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216 (45%) emergency and critical care specialists (ACVECC 
and ECVECC), 90 (19%) internists (ACVIM and ECVIM), 84 
(17%) anesthetists (ACVAA and ECVAA), 75 (16%) surgeons 
(ACVS and ECVS), 6 (1%) neurologists (ECVN), and 15 (3%) 
unspecified board-certified specialists.
Intravenous Fluid Resuscitation
Isotonic crystalloids, HES, and hypertonic saline were reported 
to be used sometimes or often for fluid resuscitation by 1,123 
(99%), 730 (64%), and 577 (51%) of respondents, respectively 
(Figure  3). Gelatin, dextran, and albumin were reported to 
be never used by 1,010 (89%), 985 (87%), and 837 (74%) of 
respondents, respectively (Figure 3). Solutions used by over 50% 
of respondents with specific disease conditions were isotonic 
crystalloids and HES in sepsis/SIRS and internal hemorrhage, 
isotonic crystalloids, and hypertonic saline in head trauma, and 
isotonic crystalloids in gastric dilatation-volvulus, gastrointesti-
nal fluid loss, and lung disease (Figure 4).
Intravenous Colloid Osmotic Support
Hydroxyethyl starch and plasma were reported to be used 
sometimes or often for COP support by 848 (75%) and 523 
(46%) of respondents, respectively (Figure 5). Gelatin, dextran, 
and albumin were reported to be never used by 1,014 (89%), 992 
(87%), and 566 (50%) of respondents, respectively. Solutions used 
by over 50% of respondents with specific disease conditions were 
HES and plasma in sepsis/SIRS and hepatic failure, and HES in 
protein-losing enteropathy and nephropathy (Figure 6).
Use of Albumin Preparations
Five and 20–25% human serum albumin was used by 262 
(23%) and 321 (28%) of respondents, respectively, and canine 
albumin was used by 182 (16%) of respondents, whereby some 
respondents used more than one albumin product. No albumin 
product was used by 505 (45%) of respondents, including 89% of 
respondents from Australia and New Zealand. Canine albumin 
was used by 21% of respondents from the USA and Canada but 
was seldom used in other geographic regions (Data Sheet S5 in 
Supplementary Material).
Choice of SC
The most frequently used SC was HES in 958 (85%), gelatin in 49 
(4%), and dextran in 31 (3%) of respondents (Figure 7). A further 
71 (6%) of respondents reported having discontinued using SCs, 
and 25 (2%) had never used SCs. Of those that had discontinued 
SC use, 65/71 (92%) previously used HES.
Institutional Policies on the Use of SCs
Only 304 (27%) reported that a general policy or guideline for 
the use of SCs existed in their workplace. Most respondents 
FigUre 5 | Frequency chart showing the relative frequency with which the 
1,134 survey respondents use intravenous solutions for colloid osmotic 
support. HES, hydroxyethyl starch; GEL, gelatin; DEX, dextran; ALB, albumin.
FigUre 4 | Frequency chart showing the type of intravenous solutions used by the 1,134 survey respondents for fluid resuscitation in specific disease conditions. 
SIRS, systemic inflammatory response syndrome; GDV, gastric dilatation-volvulus; GI loss, gastrointestinal loss.
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(726, 64%) reported no general policy and a further 104 (9%) 
did not know if one existed (Data Sheet S6 in Supplementary 
Material).
results—Part 2
Of the 1,134 respondents who completed the general part of the 
survey, 1,051 also responded to questions in the second specific 
part (Part 2).
Use of SCs
Of 947 respondents using HES, 64% used tetrastarch, 25% 
hetastarch, 8% pentastarch, and 3% did not specify HES type 
(Data Sheet S7 in Supplementary Material). Use of dextran and 
gelatin was generally limited to respondents in Europe, whereby 
gelatin was the main SC in 24% of respondents from the UK and 
dextran in 15% of respondents from Spain. The criterion reported 
most often as having high importance in influencing the choice of 
SC was availability (58% of respondents); the criterion reported 
most often as having low importance was price (42% of respond-
ents) (Figure 8).
The bolus dose of SCs reported for fluid resuscitation varied 
somewhat but was generally lower in cats than dogs (Table 1). 
Likewise, the maximum daily dose was generally lower in cats 
than in dogs (Table 2; Data Sheet S8 in Supplementary Material). 
For tetrastarch, the most frequently reported maximum daily 
doses were 11–20 and 21–30 ml/kg/day for dogs (in 46 and 27% 
of tetrastarch users, respectively), and ≤10 and 11–20  ml/kg/
day for cats (in 26 and 47% of tetrastarch users, respectively). 
Similarly, for hetastarch, the most frequently reported maximum 
daily doses were 11–20 and 21–30 ml/kg/day for dogs (in 58 and 
18% of hetastarch users, respectively), and ≤10 and 11–20 ml/
kg/day for cats (in 35 and 45% of hetastarch users, respectively).
CRI of SCs
Criteria most frequently reported to be used sometimes or often to 
guide the decision to use SCs in CRI were albumin concentration 
(85%) and presence of edema (87%, Figure 9). The criterion most 
frequently reported to be used rarely or never was COP (54%). 
The CRI dose of SCs reported by the respondents is presented 
in Table  3. A slight majority of respondents reported that they 
limited the duration of CRI to a maximum of 3 days (Table 4). 
However, 25% of respondents reported no maximum time limit.
Changes in SC Use
Of the 65 respondents who had stopped using HES, 59 (91%) had 
stopped during the past 5 years. The most frequent reason given 
FigUre 7 | Frequency chart showing the primary synthetic colloid used by 
the 1,134 survey respondents from different geographic areas.
FigUre 6 | Frequency chart showing the type of intravenous solutions used by the 1,134 survey respondents for colloid osmotic support in specific disease 
conditions. SIRS, systemic inflammatory response syndrome; PLE, protein-losing enteropathy; PLN, protein-losing nephropathy.
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was concerns regarding its safety (Table 5). Most respondents who 
had stopped using HES reported observing neither an increase 
nor a decrease in the incidence of edema, hypotension, length of 
hospitalization, or mortality in animals they treated. Although 
39% reported using vasopressors more frequently, 51% reported 
no increase in their use of vasopressors since stopping their use 
of HES. Products used instead of HES by respondents who had 
stopped using HES were isotonic crystalloids in 55 (85%), plasma 
in 41 (63%), hypertonic saline in 37 (57%), albumin in 18 (28%), 
and other/unspecified in 2 (3%) of respondents.
A further 654/927 (71%) of HES users agreed that they had 
changed their use of HES over the last 5 years but continued using 
HES. The most frequent reason was concerns regarding its safety 
(Table 5). In addition, 27/45 (60%) of gelatin users and 12/25 (48%) 
of dextran users reported changing their use of SCs. The most fre-
quent change in SC use reported by respondents using all three SCs 
was less frequent use (Figure 10). Products used instead of HES 
by respondents that had changed their use of HES were isotonic 
crystalloids in 364 (57%), hypertonic saline in 254 (40%), plasma in 
248 (39%), albumin in 116 (18%), and other/unspecified in 28 (4%) 
of respondents. Most reported neither increase nor decrease in the 
incidence of edema or hypotension, the length of hospitalization, 
or mortality since changing their use of SCs (Figure 11).
Adverse Reactions Associated with SCs
Of 927 HES users, 25 dextran users and 45 gelatin users answering 
the question, no specific adverse reaction associated with SC use 
was reported by more than 30% of respondents (Data Sheet S9 in 
Supplementary Material). The most frequently reported adverse 
reaction was increased respiratory rate/effort (29% of HES users; 
22% of gelatin users; 32% of dextran users) and impaired coagula-
tion tests for HES users (29% of respondents).
Perceived Contraindications for the Use of SCs
Of 632 HES users responding to the question, impaired renal 
function and coagulopathy were the two most common condi-
tions considered either relative or absolute contraindications for 
using HES, and more than a quarter of respondents considered 
impaired renal function and hypertension as absolute contrain-
dications (Figure  12). However, no condition was considered 
an absolute contraindication by most respondents. Of the 
27 gelatin users responding, 85% considered coagulopathy, 
hypertension, and impaired renal function as relative or absolute 
contraindications, but only hypertension was considered an 
absolute contraindication by more than a quarter of respondents 
(26%). Only 10 dextran users responded to the question. Here 
TaBle 2 | Maximum daily dose of synthetic colloids used for fluid resuscitation 
by survey respondents.
ml/kg/day hydroxyethyl starch 
usersa N (%)
gelatin users  
N (%)
Dextran users
N (%)
Dogs cats Dogs cats Dogs cats
≤10 59 (6%) 269 (29%) 4 (9%) 13 (29%) 2 (8%) 6 (24%)
11–20 460 (50%) 424 (46%) 16 (36%) 14 (31%) 8 (32%) 8 (32%)
21–30 217 (23%) 115 (12%) 14 (31%) 6 (13%) 5 (20%) 1 (4%)
31–40 70 (8%) 18 (2%) 1 (2%) 1 (2%) 2 (8%) 1 (4%)
41–50 65 (7%) 23 (3%) 2 (4%) 1 (2%) 1 (4%) 0 (0%)
>50 6 (<1%) 3 (<1%) 1 (2%) 1 (2%) 1 (4%) 0 (0%)
I don’t 
know/not 
applicable
50 (5%) 75 (8%) 7 (16%) 9 (20%) 6 (24%) 9 (36%)
Frequently reported doses (>25% of respondents) are given in bold font.
aFor details of the maximum daily dose for each HES product, see supplemental 
material.
TaBle 1 | Bolus dose of synthetic colloids used for fluid resuscitation by survey 
respondents.
ml/kg hydroxyethyl starch 
users N (%)
gelatin users  
N (%)
Dextran users 
N (%)
Dogs cats Dogs cats Dogs cats
≤5 417 (45%) 747 (81%) 11 (24%) 31 (69%) 5 (20%) 11 (44%)
6–10 367 (40%) 97 (11%) 25 (56%) 7 (16%) 8 (32%) 4 (16%)
11–15 58 (6%) 26 (3%) 2 (4%) 1 (2%) 4 (16%) 1 (4%)
16–20 60 (7%) 8 (1%) 3 (7%) 1 (2%) 4 (16%) 2 (8%)
>20 5 (1%) 3 (< 1%) 0 (0%) 0 (0%) 1 (4%) 0 (0%)
I don’t 
know/not 
applicable
20 (2%) 46 (5%) 4 (9%) 5 (11%) 3 (12%) 7 (28%)
Frequently reported doses (>25% of respondents) are given in bold font.
FigUre 8 | Frequency chart showing the relative importance of criteria reported as considerations in the selection of synthetic colloids by 1,024 survey 
respondents.
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again, hypertension was considered a relative or absolute con-
traindication by 9/10 and an absolute contraindication by 5/10 
respondents.
DiscUssiOn
This is the first major international survey on the use of SCs 
in small animals. Respondents represented a varied group of 
veterinarians with diverse qualifications and experience, work-
ing in different clinical settings. However, the majority (58%) 
of respondents were from North America, which likely created 
some degree of bias. As respondents from USA and Canada 
almost never used gelatin and dextran and represented 64% 
of HES users, survey results may be distorted toward practices 
TaBle 5 | Reasons reported by survey respondents for stopping or changing 
their use of hydroxyethyl starch (HES).
reasons given respondents N (%)
stopped 
using hes 
(N = 65)
changed 
using hes 
(N = 650)
all (N = 715)
Concerns regarding its safety 59 (91%) 536 (82%) 595 (83%)
Concerns regarding its efficacy 38 (59%) 300 (46%) 338 (47%)
Availability issues 12 (19%) 158 (24%) 170 (24%)
Other reasons 10 (15%) 18 (3%) 28 (4%)
TaBle 4 | Maximum limit for the duration of constant rate infusions of synthetic 
colloids by survey respondents.
limit respondents (N)
hydroxyethyl starch Dextran gelatin all
1 day 131 2 8 141 (21%)
3 days 332 7 13 352 (52%)
1 week 18 1 0 19 (3%)
No limit 166 1 2 169 (25%)
TaBle 3 | Constant rate infusion dose of synthetic colloids used by survey 
respondents.
ml/kg/h hydroxyethyl starch 
users N (%)
gelatin users  
N (%)
Dextran users
N (%)
Dogs cats Dogs cats Dogs cats
≤1.0 308 (48%) 432 (67%) 9 (39%) 12 (57%) 5 (45%) 9 (82%)
1.1–2.0 250 (39%) 120 (19%) 10 (43%) 3 (14%) 4 (36%) 1 (9%)
2.1–3.0 28 (4%) 14 (2%) 0 (0%) 0 (0%) 1 (9%) 0 (0%)
>3.0 15 (2%) 5 (<1%) 1 (4%) 1 (5%) 0 (0%) 0 (0%)
I don’t 
know/not 
applicable
46 (7%) 76 (12%) 3 (13%) 5 (22%) 1 (9%) 1 (9%)
Frequently reported doses (>25% of respondents) are given in bold font.
FigUre 9 | Frequency chart showing the relative importance of criteria used 
to guide the decision to use synthetic colloids as a constant rate infusion 
reported by 681 survey respondents.
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percentages of these users were affected by responses from few 
individuals.
Based on this survey, the most common resuscitation fluids 
used are isotonic crystalloids followed by HES. Similarly, isotonic 
crystalloids are preferred to SCs for fluid resuscitation in human 
ICUs (3, 10, 11), and a recent survey examining fluid therapy 
practices in dogs and cats found isotonic crystalloids were more 
commonly used than colloids (20).
Despite widespread use of HES by respondents from all 
countries, and gelatin and dextran in Europe, most respondents 
declared having no guideline or policy on the use of SCs in their 
workplace. However, our findings suggest that guidelines may 
be more common in Europe and some other geographic areas 
than in North America, possibly reflecting differences in new 
legislation for SC use in people or differences in attitudes toward 
the freedom of veterinarians to treat their cases as they see fit. 
Nevertheless, a small number of veterinarians have stopped 
using SCs and a large majority have changed their SC practices 
in recent years (mostly by using them less frequently). These 
changes were largely due to concerns regarding safety and, to a 
lesser extent, efficacy. Although evidence investigating the safety 
of SCs in small animals is growing, most published clinical stud-
ies on mortality and SC-related AKI are non-randomized and 
retrospective studies on HES. One retrospective cohort study 
in dogs showed a significantly higher incidence of AKI in dogs 
treated with 10% pentastarch (6%, n = 11) compared to dogs not 
receiving HES (2%, n = 4) (21). Conversely, four retrospective 
studies (in dogs and cats) did not find a significant difference 
in blood creatinine concentrations and AKI grades between 
critically ill animals treated with tetrastarch (6% HES-130/0.4) 
and those not receiving HES (22–25). However, one of these 
studies did find an association between the number of days of 
tetrastarch administration and an increase in AKI grade (24). 
In contrast, a CRI of 6% tetrastarch (50 ml/kg/day) in healthy 
dogs for 3 days was not found to impact renal function or cause 
lesions consistent with osmotic nephrosis (26). Nevertheless, 
most of these veterinary studies lacked statistical power due to 
small sample size, and further research is necessary to elucidate 
the real scope and severity of HES-related kidney injury in small 
animals. Only rare reports on renal side effects of gelatins and 
dextrans in small animals have been published (27). Recently, in 
a canine hemorrhagic shock model comparing dogs treated with 
6% tetrastarch, 4% gelatin, fresh whole blood, and crystalloids, 
AKI was observed in all dogs regardless of treatment, with some 
particular to this geographic area. This must be borne in mind 
when interpreting findings of this survey. Furthermore, gelatin 
and dextran users were very low in numbers, and results given as 
FigUre 11 | Frequency chart showing incidence of adverse reactions noted by survey respondents since changing their use of synthetic colloids (654 hydroxyethyl 
starch users; 27 gelatin users; 12 dextran users).
FigUre 10 | Frequency chart showing the changes in synthetic colloid use over the past 5 years and/or because of new recommendations reported by survey 
respondents (650 hydroxyethyl starch users; 27 gelatin users; 11 dextran users).
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evidence suggesting greater kidney injury in gelatin-treated 
dogs (28).
Although safety concerns lead most respondents to alter their 
use of SCs, more respondents reported availability to be of high 
importance in their choice of SC than risk of adverse effects. This 
apparent discrepancy in the relative importance given to safety 
issues likely reflects differences in opinions between those who 
did change their practice and all other SC users responding to the 
survey. Given the relative paucity of veterinary literature on HES 
safety, changes in SC practices are likely due largely to respond-
ents’ awareness of recent human studies and new guidelines in 
people. In addition, in some countries, such as the UK, HES 
solutions were recalled from the market following the European 
Medicines Agency alert in 2013 (29). In consequence, some HES 
FigUre 12 | Frequency chart showing relative and absolute contraindications for the use of hydroxyethyl starch perceived by 632 survey respondents.
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users may have been obliged to discontinue the use of HES or 
consider using other SCs.
Despite concerns regarding safety, a minority of respond-
ents reported experiencing adverse effects of SCs in their cases. 
This apparent discrepancy between human and veterinary 
medicine is likely the result of major differences in cohorts 
and treatment complexity. Furthermore, HES-related human 
RCTs were often criticized for their poor quality and more 
recently for refusal to share raw data (16, 17, 30). Of those 
respondents changing their SC practice in the present survey, 
few observed changes in the incidence of edema, hypotension, 
length of hospitalization, or mortality in their cases. However, 
some 39% of former HES users did declare an increase use 
of vasopressors. The fluid most frequently used instead of 
HES by respondents stopping or changing their use of HES 
was isotonic crystalloids. This is similar to current changes 
in fluid resuscitation practices in people reported in a recent 
international cross-sectional study (31).
Although these findings together suggest a disparity between 
perceived and reported risks associated with SCs, it is unlikely 
that many respondents logged such events in their cases. 
Moreover, increased respiratory rate/effort, impaired coagula-
tion tests, and hypertension were indeed observed by users of all 
three SCs. Previous studies have reported impaired coagulation 
tests associated with SC use in both people and small animals 
(32, 33). However, despite the increasing body of literature 
assessing coagulation impairment (33–37), no association with 
clinical bleeding has thus far been documented in dogs or cats, 
but this was noted as an observed adverse reaction by some 
respondents in the present survey. Increased respiratory rate/
effort and hypertension may be explained by volume overload 
leading to transient hypertension and increased hydrostatic 
pressure leading to pulmonary edema. Another explanation 
would be an allergic reaction although this has not been reported 
in animals to the authors’ knowledge. Gelatin and dextran are 
reported to have the most allergic potential in people (38), and 
both were occasionally associated with allergic reactions by 
survey respondents.
Coagulopathy and impaired renal function were most often 
considered contraindications for the use of HES although 
increased serum creatinine was rarely reported to be an 
observed adverse effect. This is in accordance with recent stud-
ies demonstrating a transient impairment of canine platelet 
function and whole blood coagulation (33–37) but no effect of 
HES administration on serum creatinine or urinary biomarkers 
(22–25, 27). Although sepsis, severe coagulopathy, intracranial 
hemorrhage, and impaired renal function are now considered 
absolute contraindications in many countries for the use of HES 
in people (18, 19), these were mostly considered only relative 
contraindications by respondents in this survey. Surprisingly, 
many respondents considered hypertension as either a relative or 
absolute contraindication although hypertension is not noted in 
HES product labeling, which specified only volume overload as a 
contraindication (39).
Although dosages of SCs varied, these were largely similar 
between respondents. The most commonly used HES prepara-
tion was tetrastarch, but the most frequent maximal daily dose 
used was ≤20  ml/kg/day. This may be due to previous use of 
hetastarch, for which the recommended doses in people were not 
exceeding 20  ml/kg/day (40). Furthermore, the only currently 
available veterinary HES product (6% HES 130/0.4 in 0.9% 
sodium chloride solution) has a maximal daily dose of 20 ml/kg 
(41). Whether this dose is based on extrapolation from older HES 
generations remains unclear. Interestingly, recommended doses 
for tetrastarch for people appear to vary significantly (between 30 
and 50 ml/kg/day) in different countries (39, 42, 43).
Doses used for gelatin were similar to those used for HES 
although daily limits for gelatin use are neither recommended by 
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manufacturers nor reported elsewhere to the authors’ knowledge 
(44, 45). In general, survey respondents used lower bolus doses of 
SCs in dogs and cats compared to those recommended in people 
(2, 7). While lower doses may be reasonable in cats, the reason for 
this tendency in dogs is unclear.
The preferred HES carrier solution (buffered electrolyte-
balanced versus saline) was not investigated in this survey, but 
may be important in the selection of HES products. Indeed, 
several human trials showed an association between saline-based 
colloids and acid–base and electrolytes disturbances, including 
hyperchloremia, and decreased base excess, bicarbonate and 
anion gap (46).
Most survey respondents use SCs in CRIs, a practice unique 
to veterinary medicine. Continuous rate infusion doses were 
within the currently recommended ranges of 20–30  ml/kg/day 
(7). Based on the present survey, CRIs of SCs are widely used for 
COP support in dogs and cats. As COP depends on the number of 
osmotically active particles, low molecular weight preparations, 
such as HES 130/0.4, may be expected to exert greater COP at 
similar concentrations compared to products of high molecular 
weight (2). However, a recent study in dogs with hypoalbumine-
mia showed that although plasma COP was maintained, it did not 
increase following an initial dose of 5 ml/kg 6% HES 130/0.4 over 
6h, followed by CRI of 24 ml/kg/day (47).
A limitation on the duration of SC CRIs was variably reported 
by respondents in this survey. This may reflect both varied knowl-
edge about the effects of cumulative doses and tissue storage in 
humans as well as the lack of published facts about such effects 
in dogs and cats (48).
Even though RCTs failed to show benefits of albumin infu-
sions in human ICU patients (49, 50), albumin is still widely 
recommended and used in people (31, 51). In the present survey, 
just over one half of respondents used albumin preparations, 
with human serum albumin most frequently used, despite 
potential adverse effects reported in dogs (52). Respondents 
from Australia and New Zealand rarely used albumin products 
and canine albumin was mostly used in the USA and Canada, 
suggesting marked geographic disparity in the use of albumin 
products. One reason for this is that lyophilized canine albu-
min is currently only distributed in USA, Canada, Hong Kong, 
Singapore, and Taiwan.
Data from this survey suggest that, regardless of their 
geographic location or qualifications, veterinarians continue 
using HES and other SCs. Nevertheless, and despite a lack of 
practice guidelines, a notable proportion of respondents have 
limited their use of SCs based on an awareness of potential 
deleterious effects. As little data exist in veterinary medicine, 
changes in SC practice uncovered in this survey are likely 
due largely to results of human RCTs. Given differences in 
cohorts between veterinary and human ICU patients, studies 
are needed to establish evidence-based guidelines for the use 
of SCs in dogs and cats.
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